Latest Treatment News in Neuroendocrine Tumours
Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin
Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease. [...]